Market Access News | pharmaphorum

News

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

After FDA snub, EMA backs FibroGen, Astellas' roxadustat

The EU regulator has approved FibroGen and Astellas Evrenzo for adults with anaemia caused by chronic kidney disease (CKD), just days after the FDA turned down the drug in the US.

News

NICE says yes to Novartis' Rydapt for rare blood disorder

Novartis' Rydapt has become the first and only licensed treatment for rare and life-threatening blood disorder systemic mastocytosis (SM) to be cleared for routine NHS use, after getting a

News

Jardiance gets parity with Farxiga in US as FDA clears use i...

Eli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with reduced ejection fraction (HFreF), setting up a market tussle with As

News

Amid Actemra shortage, WHO asks Roche to ensure equitable ac...

Roche's arthritis drug Actemra has become a key treatment for people with severe COVID-19, leading to shortages, and the World Health Organisation (WHO) wants the company to ensure that sup

News

scientifically visualization of a coronavirus spike protein

Merck kicks off oral COVID-19 antiviral filing in Canada

Health Canada has started a rolling review of Merck & Co's molnupiravir, an oral antiviral therapy treatment for COVID-19 partnered with Ridgeback Biotherapeutics.

News